Skip to content
ChickenStockChickenStock
Research214450
PharmaResearch logo

PharmaResearch (214450) stock

KOSDAQ · Health Care Equipment & Supplies

KRW 258,500+2.99%(+7,500)

As of the Nov 16 regular-session close (Korea)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

16.05x

P/B

3.84x

P/S

4.18x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 178.7 billionKRW 66.5 billionKRW 56.2 billion+27.1%
Q1 2026Consolidated · Filed May 15, 2026KRW 146.1 billionKRW 57.3 billionKRW 48.7 billion+25.0%
Q4 2025Consolidated · Filed Mar 19, 2026KRW 143.3 billionKRW 51.9 billionKRW 39.3 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 135.4 billionKRW 61.9 billionKRW 50.9 billion+51.8%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 140.6 billionKRW 55.9 billionKRW 42 billion+69.2%
Q1 2025Consolidated · Filed May 21, 2025KRW 116.9 billionKRW 44.7 billionKRW 36 billion+56.5%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 19, 2026KRW 536.3 billionKRW 214.4 billionKRW 168.3 billion—
FY2024Consolidated · Filed Mar 17, 2025KRW 350.1 billionKRW 126.1 billionKRW 88.9 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
4.12%
Of trading value on Nov 13, 2026
Short-sale value
KRW 1.06 billion
Previous 20-day average 6.47%
Net short position
26,619 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
872,915 shares
As of Nov 13, 2026 · 8.40% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20264.12%KRW 1.06 billion
Nov 12, 202610.82%KRW 2.67 billion
Nov 11, 20262.89%KRW 810 million
Nov 10, 20266.02%KRW 1.58 billion
Nov 9, 202612.80%KRW 3.49 billion
Nov 6, 202610.08%KRW 6.04 billion
Nov 5, 20266.34%KRW 1.58 billion
Nov 4, 20265.20%KRW 1.02 billion
Nov 3, 20266.77%KRW 730 million
Nov 2, 20266.53%KRW 1.42 billion

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

PharmaResearch (214450) stock information

KOSDAQ

PharmaResearch (214450) is listed on KOSDAQ. Its market capitalization is about KRW 2.7 trillion. On trailing-twelve-month earnings the P/E ratio is 16.05, and the P/B ratio is 3.84. Return on equity is 23.9%. These figures are computed in-house from official filings and are reference information only.

PharmaResearch — frequently asked questions

What is the P/E ratio of PharmaResearch (214450)?
On a trailing-twelve-month basis, 214450 trades at a P/E ratio of 16.05. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of PharmaResearch?
214450 has a market capitalization of about KRW 2.7 trillion. The figure moves with the share price and is refreshed each trading day.
Does PharmaResearch pay a dividend?
214450 has a dividend yield of about 1.44%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.